Biotechnology company Moderna, Inc. (MRNA) reported Friday a net loss of $1.12 billion or $2.91 per share for the fourth quarter, compared to net income of $217 million or $3.0.55 per share in the prior-year quarter.
On average, 14 analysts polled expected the company to report a loss of $2.76 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter slumped to $966 million from last year's $2.81 billion in the same quarter last year. Analysts expected revenues of $941.14 million for the quarter.
Looking ahead to fiscal 2025, the company continues to project revenues between $1.5 billion and $2.5 billion. The Street is looking for revenues of $2.22 billion for the year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.